醒脑开窍9005例(中英文新版C).ppt

研究设计：本研究为双盲、安慰剂对照、随机设计临床试验。共纳入80例发病1周内中风患者的。所有患者均接受丹芪或安慰剂治疗，4粒，3/日，病程3个月。在入组时和3个月时用经颅多谱勒（TCD）测定大脑中动脉脑血流速度，并进行Barthel指数评估。 Method： This is a double-blinded, placebo controlled, randomized study of 80 subjects included within a week of stroke onset. All subjects were given either MLC601 or placebo, 4 capsules, 3 times a day for 3 months. Cerebral blood flow within the middle cerebral artery, with blood flow velocity measured by transcranial Doppler (TCD), and Barthel index was assessed at baseline and at 3 months. 结论：合并丹芪偏瘫胶囊可以增加脑卒中患者的脑血流量，这可能与提高神经功能康复作用有关。 Conclusions： This is the first study suggesting that treatment with MLC601 may increase cerebral blood flow in stroke subjects. This may be mediated by an effect on stimulating microcirculation, an important process contributing to neuroplasticity in the central nervous system. This effect on cerebral blood flow may be associated with improvement in measures of functional recovery. 题目：NeuroAid (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia. 丹芪偏瘫胶囊与吡拉西坦对照在梗塞后同向偏盲患者的恢复作用 杂志：Neural regeneration research 2011年发表在神经再生研究杂志 影响因子：0.180 作者：Kavian Ghandehari 伊朗马什哈德医科大学神经科学研究中心 研究设计：53例大脑后动脉梗死中风患者最初纳入本研究，最后有40例病例进行最终统计分析。受试者随机分配至丹芪组和吡拉西坦组（每组20例）且接受3个月疗程的丹芪或吡拉西坦治疗，丹芪组有11名而吡拉西坦组有10名病例为右侧同向性偏盲。 Method： A total of 53 consecutive stroke patients with posterior cerebral artery territory infarction were screened and initially included in the study. In total, 40 cases were included in the final analysis. Patients were randomly assigned to MLC601 and piracetam groups (20 patients per group) and received a 3-month course of either MLC601 or piracetam, respectively. A total of 11 patients from the MLC601 group and 10 patients from the piracetam group exhibited right-sided HH. 结论：丹芪偏瘫胶囊在缩小缺损视野方面较吡拉西坦效果好。 Conclusions： These findings suggested that MLC601 was superior to piracetam for reducing visual field defects in homonymous hemianopsia patients. 题目：Safety and Efficacy of MLC601 in Ir